

press release

Novo Nordisk UK confident of supply amid Coronavirus outbreak

Gatwick, March 19 2020 – As the biggest insulin supplier in the UK and with 95 years of innovation in diabetes care, Novo Nordisk is dedicated to ensuring medicine supplies are unaffected during the current Coronavirus outbreak. Our patients, the NHS and our people are at the heart of everything we do.

We understand the pressure on the NHS at this time, and to minimise the possibility of infection moving from one service to another, from Monday 16 March, we have invested in technology to allow our teams to work from home virtually. This allows us to ensure continuity of services to our patients and to the NHS, whilst also supporting our people and their families by reducing the risk of infection through interactions at work. We are confident that we have taken all possible steps to ensure we can continue to supply the patients we serve.

We are planning for all future contingencies to ensure a strong continuation of supply to bring our essential, lifesaving, medicines into the UK. As it stands, Novo Nordisk is in a good position, with high stock levels in the UK, to continue to ensure patients get access to the medicines and treatments they need. We encourage Health Care Professionals to prescribe at a normal rate to allow us to plan our stock levels and to distribute our medicines and treatments in our normal way.

We are speaking with the Government, Department of Health and Social Care, doctors, patient group representatives and our industry trade association, the Association of the British Pharmaceutical Industry (ABPI) to ensure a united approach to supporting the country with containing this outbreak.

Pinder Sahota, Corporate Vice President of Novo Nordisk UK said, "During this unprecedented time, Novo Nordisk is doing all we can to respond to the Coronavirus outbreak. Our first commitment is to ensure that our patients continue to get access to the lifesaving medicine that they need. We believe our preparations are robust and we have taken all necessary steps to ensure continuity of supply to the UK patients we serve."

-END-

About Novo Nordisk

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people with obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries. For more information, visit novonordisk.co.uk

*Juliet Scott
Abby Purdy*

*+44 (0)7557490116
+44 (0)787 2506 607*

*zjls@novonordisk.com
Abby.Purdy@Syneoshealth.com*

Novo Nordisk Ltd
Corporate Communications

3 City Place Beehive Ring Road
Gatwick West Sussex RH6 0PA

Telephone:
+44 1293 613555

Internet:
www.novonordisk.co.uk